Ibandronate Sodium Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-26-D-0015

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

Etobicoke, Ontario, CANADA

SourceSAM
Documents1
The Defense Logistics Agency (DLA) Troop Support, operating under the Department of Defense, has issued an award notice for the procurement of Ibandronate Sodium Tablets, as indicated by procurement identifier SPE2D2-26-D-0015. This contract falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code (PSC) 6505, denoting Drugs and Biologicals. The primary objective of this procurement is to secure a reliable supply of Ibandronate Sodium Tablets, a pharmaceutical product commonly used in the treatment of bone disorders such as osteoporosis. The scope of the contract encompasses the manufacturing and delivery of these tablets to support the medical and operational needs of the Department of Defense. The intended outcome is to ensure the consistent availability of high-quality pharmaceutical preparations for military personnel and associated beneficiaries. The place of performance for this contract is specified as Etobicoke, Ontario, Canada. This location indicates that the manufacturing or distribution activities related to the contract will be conducted within this region, leveraging the capabilities of pharmaceutical manufacturers based in Etobicoke. DLA Troop Support, the contracting entity, is a federal office within the Defense Logistics Agency, responsible for providing worldwide logistics support to the military services and other federal agencies. The primary point of contact for this award is Christopher Newman, who can be reached at [email protected] or by phone at 445-737-7371. A secondary contact is Jason Wray, available at [email protected] or 445-737-6304. This award notice is currently active and was posted on July 5, 2026. The opportunity is listed on SAM.gov under Opportunity ID 6c258f5d723e4af5851594cd11c76d55, where additional details and attachments may be available for review. Contractors interested in opportunities of this nature should note that the procurement is focused on pharmaceutical manufacturing capabilities, specifically for Ibandronate Sodium Tablets, and requires compliance with all applicable regulatory standards for drug production and supply. While the notice does not specify set-aside requirements or special considerations, the federal nature of the contract implies adherence to stringent quality and security protocols throughout the contract lifecycle. For further information or to review the official award documentation, interested parties are encouraged to consult the notice on SAM.gov or contact the designated representatives.